Objective To establish a HPLC method for the determination of quercetin from different parts of L. cuncata(Dum. Cours.)G.Don.,including roots,old branches,young shoots,leaves and seeds,and to build the fingerprints. Methods The HPLC method determination of quercetin and fingerpints were establised. Results The restults showed that there were great differences be?tween the quercetin contents from different parts,with the highest contents found in seeds,followed by young shoots,leaves,old branches,and roots. The similarities of HPLC fingerprints of the medicinal material were quite different from the parts of L. cuncata (Dum.Cours.)G.Don.. The similarities were all above 0.95 for L. cuncata(Dum.Cours.)G.Don. samples,roots,old branches and young shoots below 0.85,leaves and seeds similarities below 0.60. Conclusion It was concluded that different parts(such as roots, old branches,young shoots,leaves,seeds)of L. cuncata(Dum.Cours.)G.Don. should be divided in clinical and productive practice so as to supply the scientific basis for enhancing the curative effect and reasonable utilization of the resource of L. cuncata(Dum.Cours.)G. Don.

Objective To study the prevalence,treatment policy and control of hypertension in patients with maintenance hemodialysis, and to analyze the influencing factors of hypertension control.Methods We studied the current status of 1382 patients with maintenance hemodialysis in 11 dialysis centers in Shanghai, among them 809 were male, and 573 were female.Hypertension was defined as systolic blood pressure(SBP) ≥ 140 and/or diastolic blood pressure (DBP) ≥90 mm Hg ( 1 mm Hg = 0.133 kPa).Those who had a history of hypertension and requiring antihypertensive therapy were also diagnosed as hypertension though their blood pressure was within normal range during the survey.Hypertension control was defined as blood pressure ＜ 140/90 mm Hg before each dialysis session.Results The prevalence of hypertension in the hemodialysis patients was 86.3%.The treatment rate and control rate in those patients were 96.8% and 25.5% respectively.More than half (50.4% ) of patients were treated with only one kind of anti-hypertensive drug, and 34.4% with 2 kinds, 14.2% with 3 kinds, 1.0% with 4 kinds or more.Calcium channel blocker (CCB) was the most frequently prescribed drug (61.0%), followed by angiotensin Ⅱ receptor blockers ( 56.4% ), centrally acting anti-hypertensive agent ( 26.4% ), beta blockers and alpha, beta-blockers( 14.0% ).The control rate of hypertension in those hemodialysis people was aggravated by the existence of coronary artery disease.The patients who need more kinds of antihypertensive agents have a poorer control rate of hypertension.The hypertension control rate elevated significantly with the adequate hemodialysis.Conclusions There is a very high prevalence of hypertension in maintenance hemodialysis patients.Although the treatment rate is high, the control rate is unsatisfactory.So the control of hypertension in hemodialysis patient is still a clinical challenge.Appropriate dialysis adequacy, reasonable use of erythropoietin, treatment of heart disease and judicious use of antihypertensive drugs may be helpful to improve the clinical outcome.

OBJECTIVE： To investigate inhibitory effects of lupeol on the proliferation of human breast cancer MCF-7 cells and its possible mechanism. METHODS： Taking MCF-7 cells as research object， MTT assay was used to detect the proliferation of MCF-7 cells after treated with different doses of lupeol （7.5， 15， 30， 60， 90 mg/L） for 24 h. Survival rate and IC50 of MCF-7 cells were calculated. The inverted microscope and cell cloning experiment were used to observe and detect the morphological characteristics of MCF-7 cells and clonal colony formation after treated with different doses of lupeol （15， 30， 60 mg/L） for 24 h. The rate of clonal colony formation was calculated. MTT method and Western blotting assay were used to detect the proliferation of MCF-7 cells and the expression of related regulatory proteins （ERK1/2， p-ERK1/2， JNK， p-JNK， p38 MAPK， p-p38 MAPK） after additionally treated with MAPKs signaling pathway-related regulation protein inhibitors PD98059， SP600125 and SB203580. RESULTS： After treated with 15， 30， 60， 90 mg/L lupeol， survival rates of MCF-7 cells were decreased significantly （P＜0.05 or P＜0.01）. IC50 value of the compound was 52.94 mg/L. After treated with 15， 30， 60 mg/L lupeol， the morphological characteristics of cells in each group changed， and the phenomena of cell exfoliation， floating， solid shrinkage， roundness， volume reduction and necrosis were observed. The formation of clonal colony decreased and the rate of clonal colony formation decreased significantly （P＜0.05 or P＜0.01）. When lupeol used alone， compared with control group， survival rate （60 mg/L lupeol）of MCF-7 cells was decreased significantly； the expression of p-ERK1/2 （15， 30， 60 mg/L lupeol）， p-JNK （30， 60 mg/L lupeol） and p-p38 MAPK （30， 60 mg/L lupeol） were increased significantly （P＜0.05 or P＜0.01）. After additional use of relevant inhibitors， compared with 60 mg/L lupeol group， survival rates of MCF-7 cells in combination groups were increased significantly， while relative expression of p-ERK1/2， p-JNK and p-p38 MAPK were decreased significantly （P＜0.05 or P＜0.01）. CONCLUSIONS： Lupeol can inhibit the proliferation of human breast cancer MCF-7 cells， the mechanism of which may be related to the phosphorylation of MAPKs signaling pathway-related regulatory proteins.